Tonix Starts Phase 2 Trial of Intranasal Oxytocin (TNX-1900) for Prevention of Migraine

 Tonix Pharmaceuticals, Inc. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first participant was enrolled in the Phase 2 ‘PREVENTION’ study of TNX-1900 (intranasal potentiated oxytocin) for the prevention of migraine headache in chronic migraineurs.

The double-blind, placebo-controlled study has a target enrollment of 300 participants at approximately 25 sites across the U.S. Results from a planned interim analysis are expected to be released in the fourth quarter of 2023.

https://www.biospace.com/article/releases/tonix-pharmaceuticals-initiates-enrollment-in-phase-2-prevention-study-of-potentiated-intranasal-oxytocin-tnx-1900-for-the-prevention-of-migraine-headaches-in-chronic-migraineurs/